chir-99021 and Soft-Tissue-Neoplasms

Epithelioid sarcoma (ES) is a rare disease representing <1% of soft tissue sarcomas. Current therapies are based on anthracycline alone or in combination with ifosfamide or other cytotoxic drugs. ES is still characterized by a poor prognosis with high rates of recurrence. Indeed, for years, ES survival rates have remained stagnant, suggesting that conventional treatments should be revised and improved. New therapeutic approaches are focused to target the key regulators of signaling pathways, the causative markers of tumor pathophysiology. To this end, we selected, among the drugs to which an ES cell line is highly sensitive, those that target signaling pathways known to be dysregulated in ES. In particular, we found a key role for GSK-3β, which results in up-regulation in tumor

Topics: Adult; Autophagy; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Cells, Cultured; Glycogen Synthase Kinase 3 beta; Humans; Mitosis; Mitosis Modulators; Pyridines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Survival Analysis